Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;183(6):987-988.
doi: 10.1111/bjd.19227. Epub 2020 Jun 21.

Systemic treatment in atopic dermatitis after 2018: from experienced-based treatment to evidence-based treatment?

M de Bruin-Weller  1
Affiliations
Comment

Systemic treatment in atopic dermatitis after 2018: from experienced-based treatment to evidence-based treatment?

M de Bruin-Weller. Br J Dermatol. 2020 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Wollenberg A, Oranje A, Deleuran M et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30:729-47.
    1. van der Schaft J, Politiek K, van den Reek JM et al. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 2015; 172:1621-7.
    1. van der Schaft J, Politiek K, van den Reek JM et al. Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 2016; 175:199-202.
    1. Politiek K, van der Schaft J, Coenraads PJ et al. Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br J Dermatol 2016; 174:201-3.
    1. Vermeulen FM, Gerbens LAA, Schmitt J et al. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema. Br J Dermatol 2020; 183:1090-9.